Literature DB >> 8485724

Expression of HLA class I antigens in sporadic adenomas and histologically normal mucosa of the colon.

G J Tsioulias1, G Triadafilopoulos, E Goldin, E D Papavassiliou, S Rizos, P Bassioukas, B Rigas.   

Abstract

The loss of HLA antigens by neoplastic cells is considered important for tumor growth and metastasis, inasmuch as it may allow tumors to escape immune surveillance. We have observed reduced expression of HLA antigens in sporadic colon cancer and adenomas from familial adenomatous polyposis patients. We now studied the expression of HLA class I antigens in patients with sporadic adenomas, which are precursors of colorectal cancer. Expression of HLA class I antigens was studied by immunohistochemistry in (a) sporadic colon adenomas, (b) histologically normal mucosa distant from the adenomas, (c) histologically normal colonic mucosa from patients with history of sporadic colon adenomas, and (d) colonic mucosa from normal subjects. HLA class I antigen expression was moderately reduced in 56% and severely reduced in 44% of the adenomas; this reduction was significant when compared to controls (P < 0.0001). The reduction of HLA class I expression in adenomas was related to the grade of dysplasia of the adenomas. HLA class I expression of normal appearing mucosa was decreased in 76% of patients with adenoma (P < 0.0001) and in 54% of patients with history of adenoma (P < 0.005) compared to normal controls. These changes were antigen specific, inasmuch as the expression of carcinoembryonic antigen, a surface antigen, was not affected. Our findings suggest that reduced HLA class I expression is an early event in the cell transformation process from normal to neoplastic state, preceding in many cases the onset of histological changes. HLA class I could be potentially used as a premalignant marker in the colon.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485724

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer.

Authors:  N Arber; R N DuBois
Journal:  Curr Gastroenterol Rep       Date:  1999-10

3.  Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.

Authors:  S Pion; P Fontaine; C Baron; M Gyger; C Perreault
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

4.  Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases.

Authors:  A Maiorana; A M Cesinaro; R A Fano; G Collina
Journal:  Clin Exp Metastasis       Date:  1995-01       Impact factor: 5.150

5.  The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development.

Authors:  B Rigas; G J Tsioulias; C Allan; R K Wali; T A Brasitus
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

6.  Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer.

Authors:  Benjamin Goeppert; Lena Frauenschuh; Manuela Zucknick; Stephanie Roessler; Arianeb Mehrabi; Mohammadreza Hafezi; Albrecht Stenzinger; Arne Warth; Anita Pathil; Marcus Renner; Peter Schirmacher; Wilko Weichert
Journal:  Br J Cancer       Date:  2015-10-13       Impact factor: 7.640

Review 7.  HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.

Authors:  Per Anderson; Natalia Aptsiauri; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Cell Mol Immunol       Date:  2021-01-20       Impact factor: 22.096

Review 8.  STING: a master regulator in the cancer-immunity cycle.

Authors:  Yuanyuan Zhu; Xiang An; Xiao Zhang; Yu Qiao; Tongsen Zheng; Xiaobo Li
Journal:  Mol Cancer       Date:  2019-11-04       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.